Comparative studies of clinical outcomes and quality of life between the two routes of administration in patients with HER2-positive cancer could be carried out, as well as cost-effectiveness analyses that consider both direct and indirect costs, including the impact on the patient's quality of life. Here, ERBB2 is linked to cancer.